T-Lymphocyte – Talk Bio

Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods

2 weeks ago talkbio0Tagged Autoimmune Diseases, conditioning regimens, covalent biologics, drug conjugates, engagers, Enlaza, gene therapy, T-Lymphocyte, War-Lock platform

Vertex Pharmaceuticals; Enlaza Therapeutics; autoimmune diseases; gene therapy; conditioning regimens; War-Lock platform; covalent biologics; drug conjugates; T-cell engagers; biotech alliance

Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack

5 months ago talkbio0Tagged B-Lymphocytes, Boehringer, CUE-501, Cues, Depletion, paying, T-Lymphocyte

Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte

Hillstar Bio Launches with $67M to Develop Precision Immunotherapies for Autoimmune Diseases

6 months ago talkbio0Tagged Autoimmune Diseases, Axial, Precision Immunology, Series, Spondylarthritis, T-Lymphocyte, TRBV9 gene

Precision immunology, autoimmune diseases, TRBV9+ T cells, axial spondyloarthritis, Series A funding

AbbVie and Xilio Therapeutics Forge $2.1 Billion Partnership for Novel Tumor-Activated Immunotherapies

7 months ago talkbio0Tagged AbbVie, Collaboration, Drug Development, engagers, Immunotherapy, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, immunotherapy, tumor-activated, T cell engagers, collaboration, oncology, drug development

AbbVie and Xilio Therapeutics Collaborate on $2.1B Deal for Novel Tumor-Activated Immunotherapies

7 months ago talkbio0Tagged AbbVie, biobucks, Collaboration, engagers, Neoplasms, T-Lymphocyte, tumor-activated

AbbVie, Xilio Therapeutics, T-cell engagers, tumor-activated immunotherapies, oncology, collaboration, biobucks deal

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

8 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases

8 months ago talkbio0Tagged Capital, Chronic Immune-Mediated Diseases, engagers, immune reset, innovations, Monograph, NEA, Norwest, Ouro Medicines, Partner in relationship, SmithKline Beecham, T-Lymphocyte, TPG, venture

Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners